Teva Pharma (NYSE: TEVA) reported Q4 EPS of $0.71, in-line with the analyst estimate of $0.71. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.88 billion.

GUIDANCE:

Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus of $2.51. Teva Pharma sees FY2023 revenue of $14.8-15.4 billion, versus the consensus of $15.2 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.